67087-48-3Relevant academic research and scientific papers
Copper promoted: N -alkylation of sulfoximines with alkylboronic acid under mild conditions
Gupta, Surabhi,Chaudhary, Priyanka,Muniyappan, Nalluchamy,Sabiah, Shahulhameed,Kandasamy, Jeyakumar
supporting information, p. 8493 - 8498 (2017/10/27)
The copper meditated N-methylation of sulfoximines using methylboronic acid is reported. The reactions provide excellent yields in a short span of time under mild conditions. The optimized conditions were also found to be suitable for the N-alkylation of sulfoximine with different alkylboronic acids. In addition, N-methylation and cyclopropylation of the bioactive l-methionine sulfoximine derivative was demonstrated under standard reaction conditions.
Direct Access to N -Alkylsulfoximines from Sulfides by a Sequential Imidation/Oxidation Procedure
Dannenberg, Carl Albrecht,Bizet, Vincent,Bolm, Carsten
, p. 1951 - 1959 (2015/06/30)
Synthetically relevant N-alkyl-substituted sulfoximines are directly prepared from sulfides by an unprecedented one-pot imidation/oxidation sequence. In situ generated N-bromoalkylamines serve as readily accessible imidating agents leading to N-alkylsulfiliminium bromides that are subsequently oxidized providing the corresponding N-alkylsulfoximines. In this manner, gram quantities of the products can be obtained in a short period of time avoiding the use of toxic and cumbersome to handle alkylating reagents.
ALKYNYLPYRIMIDINES AS TIE2 KINASE INHIBITORS
-
, (2009/01/23)
The invention relates to alkynylpyrimidines according to the general formula (I) in which A, R1, R2, R3, R4, R5, and R6 are as defined in the claims, to pharmaceutical compositions comprising said alkynylpyrimidines, to methods of preparing said alkynylpyrimidines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 and VEGFR2 signalling.
SULFOXIMINE-SUBSTITUTED PYRIMIDINES , THEIR PREPARATION AND USE AS DRUGS
-
Page/Page column 118-119, (2010/11/27)
The invention relates to sulfoximine-substituted pyrimidines of the general Formula (I) processes for the preparation thereof and their use as kinase inhibitors for treating for example cancer or inflammation.
Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
-
Page/Page column 45, (2010/11/28)
The invention relates to sulfoximine-substituted pyrimidines of the general formula I processes for the preparation thereof and their use as drugs.
